Cat. #161952
VCaP 3 [DCC E] CRPC Cell line
Cat. #: 161952
Availability: 8-10 weeks
Organism: Human
Tissue: Prostate
Disease: Cancer
Model: Tumour Cell Line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Wytske van Weerden
Institute: Erasmus University Medical Centre
Primary Citation: Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: VCaP 3 [DCC E] CRPC Cell line
- Research fields: Cancer
- Parental cell: VCaP
- Organism: Human
- Tissue: Prostate
- Disease: Cancer
- Model: Tumour Cell Line
- Model description: CRPC model
- Receptors of note: Androgen receptor
- Description: CRPC VCaP cell lines (15 sublines made resistant to common antiandrogens through long-term passaging) - Dextran-coated charcoal-stripped FCS (DCC E). The VCaP DCC cell line was generated by long-term culturing of VCaP cells in androgen depleted medium containing dextran-coated charcoal-stripped foetal calf serum (DCC-FCS). This cell line is subclone E. These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy in CRPC.
- Application: Tumour Modelling
Applications
- Application: Tumour Modelling
Handling
- Growth medium: RPMI1640 + 10% DCC-FCS
- Storage conditions: liquid N2
- Cultured in antibiotics: 1% Penicillin/Streptomycin
References
- Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769715
